Three-Pronged attack on Tough-to-Treat colon cancer
Disease control
Recruiting now
This early-stage study is testing a new three-part treatment for advanced colorectal cancer that has stopped responding to standard therapies. It combines an immunotherapy drug, a targeted cancer drug, and a personalized cell therapy made from the patient's own immune cells. The …
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC